Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Eisai Expands Deal with Arena, Gets All Global Rights to Belviq
January 6, 2017
- Kyowa Kirin’s KRN23 Filed in Europe for X-Linked Hypophosphatemia
January 6, 2017
- SSP Now under Sanofi Group in Japan after BI Biz Swap
January 6, 2017
- ASKA Eyes 33% Rise in Women’s Health Sales by FY2020
January 5, 2017
- ASKA Ties Up with TesoRx on Oral Testosterone Therapy
January 5, 2017
- Takeda Makes Foray into Consumer Diagnostic Biz with Ovulation, Pregnancy Tests
December 28, 2016
- Opdivo Filed for Gastric Cancer in Japan: Ono
December 28, 2016
- AZ Returns Meropenem Rights in Southeast Asia, HK to Sumitomo Dainippon
December 27, 2016
- SBI, Kubota to Form JV for Ophthalmic Drugs, Devices
December 27, 2016
- Aspen Japan to Launch Imigran AG on Jan. 16
December 27, 2016
- 40 Billion Yen Sales for Oncology Business in FY2020 Achievable: Daiichi Sankyo
December 27, 2016
- Towa to Discontinue Marketing Cabergoline Generic due to Failure in Dissolution Testing
December 27, 2016
- Eisai, Keio Univ. Seal 10-Year Collaboration on Dementia Research
December 26, 2016
- Ono In-Licenses OmniAb Antibody Producing Platforms from US Biotech
December 26, 2016
- Chugai Licenses Marine-Derived Cancer Med from Spain’s PharmaMar
December 26, 2016
- Hemophilia Med Emicizumab Hits PIII Target; Global Filings Slated for 2017
December 26, 2016
- Keytruda Filed for Hodgkin’s Lymphoma, 3rd Indication in Japan
December 26, 2016
- Sawai Prevails in Patent Suit over Elplat
December 26, 2016
- New Indication Added to Plavix Generics to Fill Gap with Originator
December 22, 2016
- Janssen’s MM Med Daratumumab Filed in Japan
December 22, 2016
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…